Kiora Pharmaceuticals
KPRX
11 hedge funds and large institutions have $7.44M invested in Kiora Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
10% more funds holding
Funds holding: 10 → 11 (+1)
0% less ownership
Funds ownership: 0.12% → 0.11% (-0%)
21% less capital invested
Capital invested by funds: $9.39M → $7.44M (-$1.95M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSWM
Golden State Wealth Management
Santa Ana,
California
|
+$7.87K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$267K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9.44K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $7.12M | – | – | – |
|
2
Geode Capital Management
Boston,
Massachusetts
| $137K | – | – | – |
|
3
BlackRock
New York
| $103K | – | – | – |
|
4
Vanguard Group
Malvern,
Pennsylvania
| $46K | – | – | – |
|
5
US Bancorp
Minneapolis,
Minnesota
| $11K | – | – | – |
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| $7K | – | – | – |
|
|
GSWM
7
Golden State Wealth Management
Santa Ana,
California
| $7K | +$7.87K | +5 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $6K | +$6.29K | +4 | New |
|
|
9
UBS Group
Zurich,
Switzerland
| $2K | -$9.44K | -6 | -86% |
|
10
Morgan Stanley
New York
| $2K | – | – | – |
|
11
Osaic Holdings
Scottsdale,
Arizona
| $2K | – | – | – |
|
|
12
Renaissance Technologies
New York
| – | -$267K | -154 | Closed |
|
KPRX Hedge Fund Activity: Q3 2020 in Review
11 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q3 2020, worth a combined $7.44M — down 21% from $9.39M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new KPRX positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Golden State Wealth Management, opening a new position worth an estimated $7.87K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $267K sold.
- 11 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q3 2020, up from 10 in Q2 2020.
- Funds reported $7.44M of Kiora Pharmaceuticals stock for Q3 2020, down 21% quarter-over-quarter.
- 2 funds opened new Kiora Pharmaceuticals positions in Q3 2020 and 1 closed out, a net change of +1 holder.
- The largest Kiora Pharmaceuticals buyer in Q3 2020 was Golden State Wealth Management, an estimated $7.87K added.
- The largest Kiora Pharmaceuticals seller in Q3 2020 was Renaissance Technologies, an estimated $267K sold.
Based on aggregated 13F filings for Q3 2020.